Development and evaluation of the novel topical formulation containing Bakuchiol for enhanced skin delivery

Ali Asram Sağıroğlu; Beyza Sümeyye Aydın

Development and evaluation of the novel topical formulation containing Bakuchiol for enhanced skin delivery

Abstract

This study investigates the encapsulation of bakuchiol, a renowned compound for hyperpigmentation treatment, utilizing transfersomes as a delivery system. The transfersomes were fabricated using the thin-film hydration technique and subjected to thorough characterization across various parameters. The resulting transfersome formulation, after optimization, demonstrated notably high encapsulation efficiencies, with bakuchiol registering at 86.7±3.6%, accompanied by a narrow particle size distribution (179.9 ± 5.4 nm). In vitro release studies unveiled cumulative release percentages of 71.98±6.52% for bakuchiol over a 24-hour period. Ex vivo permeation studies further affirmed heightened retention of bakuchiol within the skin layers compared to control group. Stability assessments indicated that the optimized transfersome remained stable at 5°C for at least 90 days. These findings underscore the remarkable potential of transfersomes in facilitating the delivery of bakuchiol, offering a compelling and viable alternative for hyperpigmentation formulations.

Keywords

References

[1] Rigopoulos D, Gregoriou S, Katsambas A. Hyperpigmentation and melasma. J Cosmet Dermatol 2007;6:195–202. https://doi.org/10.1111/j.1473-2165.2007.00321.X.
[2] Chaowattanapanit S, Silpa-archa N, Kohli I, Lim HW, Hamzavi I. Postinflammatory hyperpigmentation: A comprehensive overview: Treatment options and prevention. J Am Acad Dermatol 2017;77:607–621. https://doi.org/10.1016/j.jaad.2017.01.036.
[3] Callender VD, St.Surin-Lord S, Davis EC, Maclin M. Postinflammatory hyperpigmentation: Etiologic and therapeutic considerations. Am J Clin Dermatol 2011;12:87–99. https://doi.org/10.2165/11536930.
[4] Pandya AG, Guevara IL. Disorders of hyperpigmentation. Dermatol Clin. 2000;18:91–98. https://doi.org/10.1016/S0733-8635(05)70150-9.
[5] Pérez-Bernal A, Muñoz-Pérez MA, Camacho F. Management of facial hyperpigmentation. Am J Clin Dermatol. 2000;1:261–268. https://doi.org/10.2165/00128071-200001050-00001.
[6] Briganti S, Camera E, Picardo M. Chemical and ınstrumental approaches to treat hyperpigmentation. Pigment Cell Res. 2003;16:101–110. https://doi.org/10.1034/J.1600-0749.2003.00029.X.
[7] Vashi NA, Kundu RV. Facial hyperpigmentation: causes and treatment. Br J Dermatol. 2013;169:41–56. https://doi.org/10.1111/bjd.12536.
[8] Balkrishnan R, McMichael AJ, Camacho FT, Saltzberg F, Housman TS, Grummer S, Feldman SR, Chren MM. Development and validation of a health-related quality of life instrument for women with melasma. Br J Dermatol. 2003;149(3):572-577. https://doi.org/ 10.1046/j.13652133.2003.05419.x.

[9] Rossi AM, Perez MI. Treatment of hyperpigmentation. Facial Plast Surg Clin North Am. 2011;19:313–324. https://doi.org/10.1016/j.fsc.2011.05.010.
[10] Puyana C, Chandan N, Tsoukas M. Applications of bakuchiol in dermatology: Systematic review of the literature. J Cosmet Dermatol. 2022;21:6636–6643. https://doi.org/10.1111/jocd.15420.
[11] Dhaliwal S, Rybak I, Ellis SR, Notay M, Trivedi M, Burney W, Vaughn AR, Nguyen M, Reiter P, Bosanac S, Yan H, Foolad N, Sivamani RK. Prospective, randomized, double‐blind assessment of topical bakuchiol and retinol for facial photoageing. Br J Dermatol. 2019;180:289–296. https://doi.org/10.1111/bjd.16918.
[12] Nong Y, Gahoonia N, Rizzo J, Burney W, Sivamani RK, Maloh J. Prospective evaluation of a topical botanical skin care regimen on mild to moderate facial and truncal acne and mood. J Clin Med. 2023;12:1484. https://doi.org/10.3390/jcm12041484.
[13] Jafernik K, Halina E, Ercisli S, Szopa A. Characteristics of bakuchiol - the compound with high biological activity and the main source of its acquisition - Cullen corylifolium (L.) Medik. Nat Prod Res. 2021;35:5828–5842. https://doi.org/10.1080/14786419.2020.1837813.
[14] Ko D, Wang RF, Ozog D, Lim HW, Mohammad TF. Disorders of hyperpigmentation. Part II. Review of management and treatment options for hyperpigmentation. J Am Acad Dermatol. 2023;88:291–320. https://doi.org/10.1016/j.jaad.2021.12.065.
[15] Cariola A, El Chami M, Granatieri J, Valgimigli L. Anti-tyrosinase and antioxidant activity of meroterpene bakuchiol from Psoralea corylifolia (L.). Food Chem. 2023;405:134953. https://doi.org/10.1016/j.foodchem.2022.134953.
[16] Budama-Kilinc Y, Gok B, Kecel-Gunduz S, Altuntas E. Development of nanoformulation for hyperpigmentation disorders: Experimental evaluations, in vitro efficacy and in silico molecular docking studies. Arab J Chem. 2022;15:104362. https://doi.org/10.1016/j.arabjc.2022.104362.
[17] Hatem S, El Hoffy NM, Elezaby RS, Nasr M, Kamel AO, Elkheshen SA. Background and different treatment modalities for melasma: Conventional and nanotechnology-based approaches. J Drug Deliv Sci Technol. 2020;60:101984. https://doi.org/10.1016/j.jddst.2020.101984.
[18] Treatment of hyperpigmentation after burn: A literature review. Treatment of hyperpigmentation after burn: A literature review. Burns. 2022;48:1055–1068. https://doi.org/10.1016/j.burns.2022.04.017.
[19] Zolghadri S, Beygi M, Mohammad TF, Alijanianzadeh M, Pillaiyar T, Garcia-Molina P, Garcia-Canovas F, Munoz-Munoz J, Saboury AA. Targeting tyrosinase in hyperpigmentation: Current status, limitations and future promises. Biochem Pharmacol. 2023;212:115574. https://doi.org/10.1016/j.bcp.2023.115574.
[20] Egbaria K, Weiner N. Liposomes as a topical drug delivery system. Adv Drug Deliv Rev. 1990;5:287–300. https://doi.org/10.1016/0169-409X(90)90021-J.
[21] Roberts MS, Cheruvu HS, Mangion SE, Alinaghi A, Benson HAE, Mohammed Y, Holmes A, van der Hoek J, Pastore M, Grice JE. Topical drug delivery: History, percutaneous absorption, and product development. Adv Drug Deliv Rev. 2021;177:113929. https://doi.org/10.1016/j.addr.2021.113929.
[22] Chaturvedi S, Garg A. An insight of techniques for the assessment of permeation flux across the skin for optimization of topical and transdermal drug delivery systems. J Drug Deliv Sci Technol. 2021;62:102355. https://doi.org/10.1016/j.jddst.2021.102355.
[23] Ghasemiyeh P, Mohammadi-Samani S, Noorizadeh K, Zadmehr O, Rasekh S, Mohammadi-Samani S, Deghghan D. Novel topical drug delivery systems in acne management: Molecular mechanisms and role of targeted delivery systems for better therapeutic outcomes. J Drug Deliv Sci Technol. 2022;74:103595. https://doi.org/10.1016/j.jddst.2022.103595.
[24] Szumała P, Macierzanka A. Topical delivery of pharmaceutical and cosmetic macromolecules using microemulsion systems. Int J Pharm. 2022;615:121488. https://doi.org/10.1016/j.ijpharm.2022.121488.
[25] Li J, Duan N, Song S, Nie D, Yu M, Wang J, Xi Z, Li J, Sheng Y, Xu C, Wei Y, Gan Y. Transfersomes improved delivery of ascorbic palmitate into the viable epidermis for enhanced treatment of melasma. Int J Pharm. 2021;608:121059. https://doi.org/10.1016/j.ijpharm.2021.121059.
[26] Chavda VP, Acharya D, Hala V, Daware S, Vora LK. Sunscreens: A comprehensive review with the application of nanotechnology. J Drug Deliv Sci Technol. 2023;86:104720. https://doi.org/10.1016/j.jddst.2023.104720.
[27] Yasmeen, Iqubal MK, Khan MA, Agarwal NB, Ali J, Baboota S. Nanoformulations-based advancement in the delivery of phytopharmaceuticals for skin cancer management. J Drug Deliv Sci Technol. 2021;66:102912. https://doi.org/10.1016/j.jddst.2021.102912.
[28] Santos AC, Rodrigues D, Sequeira JAD, Pereira I, Simões A, Costa D, Peixoto D, Costa G, Veiga F.Nanotechnological breakthroughs in the development of topical phytocompounds-based formulations. Int J Pharm 2019;572:118787. https://doi.org/10.1016/j.ijpharm.2019.118787.
[29] Kouassi MC, Grisel M, Gore E. Multifunctional active ingredient-based delivery systems for skincare formulations: A review. Colloids Surf B Biointerfaces. 2022;217:112676. https://doi.org/10.1016/j.colsurfb.2022.112676.
[30] Nagula RL, Wairkar S. Recent advances in topical delivery of flavonoids: A review. J Control Release. 2019;296:190–201. https://doi.org/10.1016/j.jconrel.2019.01.029.
[31] Küchler S, Abdel-Mottaleb M, Lamprecht A, Radowski MR, Haag R, Schäfer-Korting M. Influence of nanocarrier type and size on skin delivery of hydrophilic agents. Int J Pharm. 2009;377:169–72. https://doi.org/10.1016/j.ijpharm.2009.04.046.
[32] Prow TW, Grice JE, Lin LL, Faye R, Butler M, Becker W, Wurm EM, Yoong C, Robertson TA, Soyer HP, Roberts MS. Nanoparticles and microparticles for skin drug delivery. Adv Drug Deliv Rev. 2011;63:470–491. https://doi.org/10.1016/j.addr.2011.01.012.
[33] El Zaafarany GM, Awad GAS, Holayel SM, Mortada ND. Role of edge activators and surface charge in developing ultradeformable vesicles with enhanced skin delivery. Int J Pharm. 2010;397:164–172. https://doi.org/10.1016/j.ijpharm.2010.06.034.
[34] Magarkar A, Dhawan V, Kallinteri P, Viitala T, Elmowafy M, Róg T, Bunker A. Cholesterol level affects surface charge of lipid membranes in saline solution. Sci Reports. 2014 41 2014;4:1–5. https://doi.org/10.1038/srep05005.
[35] Ascenso A, Raposo S, Batista C, Cardoso P, Mendes T, Praça FG, Bentley MV, Simões S. Development, characterization, and skin delivery studies of related ultradeformable vesicles: Transfersomes, ethosomes, and transethosomes. Int J Nanomedicine. 2015;10:5837–5851. https://doi.org/10.2147/ijn.S86186.
[36] Ahad A, Al-Saleh AA, Al-Mohizea AM, Al-Jenoobi FI, Raish M, Yassin AEB, Alam MA. Formulation and characterization of Phospholipon 90 G and tween 80 based transfersomes for transdermal delivery of eprosartan mesylate. Pharm Dev Technol. 2018;23:787–793. https://doi.org/10.1080/10837450.2017.1330345.
[37] Al Shuwaili AH, Rasool BKA, Abdulrasool AA. Optimization of elastic transfersomes formulations for transdermal delivery of pentoxifylline. Eur J Pharm Biopharm. 2016;102:101–114. https://doi.org/10.1016/J.ejpb.2016.02.013.
[38] Cevc G, Schätzlein A, Richardsen H. Ultradeformable lipid vesicles can penetrate the skin and other semi-permeable barriers unfragmented. Evidence from double label CLSM experiments and direct size measurements. Biochim Biophys Acta - Biomembr. 2002;1564:21–30. https://doi.org/10.1016/S0005-2736(02)00401-7.
[39] Cevc G. Lipid vesicles and other colloids as drug carriers on the skin. Adv Drug Deliv Rev. 2004;56:675–711. https://doi.org/10.1016/j.addr.2003.10.028.
[40] Gupta A, Aggarwal G, Singla S, Arora R. Transfersomes: A novel vesicular carrier for enhanced transdermal delivery of sertraline: Development, characterization, and performance evaluation. Sci Pharm. 2012;80:1061. https://doi.org/10.3797/scipharm.1208-02.
[41] Shamim MA, Shahid A, Sardar PK, Yeung S, Reyes J, Kim J, Parsa C, Orlando R, Wang J, Kelly KM, Meyskens FL Jr, Andresen BT, Huang Y. Transfersome encapsulated with the R-carvedilol enantiomer for skin cancer chemoprevention. Nanomater. 2023;13. https://doi.org/10.3390/nano13050929.
[42] Chen M, Shamim MA, Shahid A, Yeung S, Andresen BT, Wang J, Nekkanti V, Meyskens FL Jr, Kelly KM, Huang Y. Topical delivery of carvedilol loaded nano-transfersomes for skin cancer chemoprevention. Pharmaceutics. 2020;12:1–17. https://doi.org/10.3390/pharmaceutics12121151.
[43] Ruckmani K, Jayakar B, Ghosal SK. Nonionic surfactant vesicles (niosomes) of cytarabine hydrochloride for effective treatment of leukemias: Encapsulation, storage, and in vitro release. Drug Dev Ind Pharm. 2000;26:217–222. https://doi.org/10.1081/ddc-100100348.
[44] Varelas CG, Dixon DG, Steiner CA. Zero-order release from biphasic polymer hydrogels. J Control Release. 1995;34:185–192. https://doi.org/10.1016/0168-3659(94)00085-9.
[45] England CG, Miller MC, Kuttan A, Trent JO, Frieboes HB. Release kinetics of paclitaxel and cisplatin from two and three layered gold nanoparticles. Eur J Pharm Biopharm. 2015;92:120–129. https://doi.org/10.1016/j.ejpb.2015.02.017.
[46] Hixson AW, Crowell JH. Dependence of reaction velocity upon surface and agitation. Ind Eng Chem. 1931;23:923–931. https://doi.org/10.1021/ie50260a018.
[47] England CG, Miller MC, Kuttan A, Trent JO, Frieboes HB. Release kinetics of paclitaxel and cisplatin from two and three layered gold nanoparticles. Eur J Pharm Biopharm. 2015;92:120–129. https://doi.org/10.1016/j.ejpb.2015.02.017.

Details

Primary Language

English

Subjects

Pharmaceutical Biotechnology, Pharmaceutical Delivery Technologies

Journal Section

Research Article

Authors

Ali Asram Sağıroğlu ^*
0000-0002-6960-6364
Türkiye

Beyza Sümeyye Aydın
0000-0003-4066-1105
Türkiye

Publication Date

June 28, 2025

Submission Date

October 30, 2023

Acceptance Date

December 1, 2023

Published in Issue

Year 2024 Volume: 28 Number: 2

IZ

https://izlik.org/JA85PR43YJ

Cite

RIS / Bibtex

APA

Sağıroğlu, A. A., & Aydın, B. S. (2025). Development and evaluation of the novel topical formulation containing Bakuchiol for enhanced skin delivery. Journal of Research in Pharmacy, 28(2), 470-481. https://izlik.org/JA85PR43YJ

AMA

1.Sağıroğlu AA, Aydın BS. Development and evaluation of the novel topical formulation containing Bakuchiol for enhanced skin delivery. J. Res. Pharm. 2025;28(2):470-481. https://izlik.org/JA85PR43YJ

Chicago

Sağıroğlu, Ali Asram, and Beyza Sümeyye Aydın. 2025. “Development and Evaluation of the Novel Topical Formulation Containing Bakuchiol for Enhanced Skin Delivery”. Journal of Research in Pharmacy 28 (2): 470-81. https://izlik.org/JA85PR43YJ.

EndNote

Sağıroğlu AA, Aydın BS (June 1, 2025) Development and evaluation of the novel topical formulation containing Bakuchiol for enhanced skin delivery. Journal of Research in Pharmacy 28 2 470–481.

IEEE

[1]A. A. Sağıroğlu and B. S. Aydın, “Development and evaluation of the novel topical formulation containing Bakuchiol for enhanced skin delivery”, J. Res. Pharm., vol. 28, no. 2, pp. 470–481, June 2025, [Online]. Available: https://izlik.org/JA85PR43YJ

ISNAD

Sağıroğlu, Ali Asram - Aydın, Beyza Sümeyye. “Development and Evaluation of the Novel Topical Formulation Containing Bakuchiol for Enhanced Skin Delivery”. Journal of Research in Pharmacy 28/2 (June 1, 2025): 470-481. https://izlik.org/JA85PR43YJ.

JAMA

1.Sağıroğlu AA, Aydın BS. Development and evaluation of the novel topical formulation containing Bakuchiol for enhanced skin delivery. J. Res. Pharm. 2025;28:470–481.

MLA

Sağıroğlu, Ali Asram, and Beyza Sümeyye Aydın. “Development and Evaluation of the Novel Topical Formulation Containing Bakuchiol for Enhanced Skin Delivery”. Journal of Research in Pharmacy, vol. 28, no. 2, June 2025, pp. 470-81, https://izlik.org/JA85PR43YJ.

Vancouver

1.Ali Asram Sağıroğlu, Beyza Sümeyye Aydın. Development and evaluation of the novel topical formulation containing Bakuchiol for enhanced skin delivery. J. Res. Pharm. [Internet]. 2025 Jun. 1;28(2):470-81. Available from: https://izlik.org/JA85PR43YJ